Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Inventors

Marom, Ehud • Rubnov, Shai

Assignees

Mapi Pharma Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-RE50301-E1

Patent

Publication Date

2025-02-18

Expiration Date


Abstract

Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.

Core Innovation

The invention is a long-acting parenteral pharmaceutical composition containing a therapeutically effective amount of a pharmaceutically acceptable salt of glatiramer in a sustained-release depot form. The depot releases a therapeutically effective amount over about one week to about six months. The disclosed formulations particularly include glatiramer acetate in biodegradable polymer microparticles, including PLGA microparticles.

The disclosed use is treatment of multiple sclerosis with a sustained-release glatiramer depot. The depot is intended to allow less frequent administration and reduce local or systemic side effects while maintaining or improving efficacy. The background section is not included in the provided content, so the problem described there is not explicitly available.

Claims Coverage

The relevant claims identify four independent claims comprising four inventive features directed to sustained-release glatiramer depot compositions and methods for treating multiple sclerosis.

Long-acting glatiramer depot composition

A parenteral pharmaceutical composition contains a therapeutically effective amount of a pharmaceutically acceptable salt of glatiramer in a sustained-release depot form that releases a therapeutically effective amount over about one week to about six months.

Parenteral treatment of multiple sclerosis

A method of treating multiple sclerosis comprises parenterally administering a long-acting composition containing a therapeutically effective amount of a pharmaceutically acceptable salt of glatiramer in a sustained-release depot form that releases the salt over about one week to about six months.

Multiple sclerosis treatment using glatiramer acetate and PLGA

A method of treating multiple sclerosis uses a parenterally administered sustained-release depot containing glatiramer acetate and a PLGA carrier, with release of a therapeutically effective amount over one week to six months.

Injectable glatiramer acetate microparticle composition

A long-acting parenteral composition contains glatiramer acetate in a PLGA carrier, in a sustained-release depot form prepared as a suspension for injection comprising microparticles, with release over about one week to about six months.

The independent claims cover sustained-release glatiramer depot compositions and parenteral treatment of multiple sclerosis, including a more specifically defined glatiramer acetate and PLGA microparticle composition.

Stated Advantages

The depot formulation is stated to permit less frequent administration.

The formulation is stated to reduce local or systemic side effects while maintaining or improving efficacy.

In the reported mouse EAE model, the depot formulation showed greater disease inhibition than conventional glatiramer at the tested dose, with reduced clinical scores and prevention of weight loss.

Documented Applications

Treatment of multiple sclerosis using parenteral administration of a long-acting, sustained-release glatiramer depot.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.